Lifog

Latanoprost, the active ingredient in Lifog, is a prostaglandin analog presented as an ophthalmic solution for ophthalmic use. It lowers intra‑ocular pressure in adults with primary open‑angle glaucoma or ocular hypertension and is administered once daily in the evening.

GNH USA supplies Lifog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for importers. Its global logistics network ensures timely delivery to authorized healthcare facilities across multiple continents.

Latanoprost is used to lower intra‑ocular pressure in glaucoma‑related conditions.

- Primary open-angle glaucoma: reduces intra‑ocular pressure, thereby slowing optic nerve damage and preserving visual field. - Ocular hypertension: lowers intra‑ocular pressure to levels that reduce the risk of developing glaucoma over time. - Secondary open-angle glaucoma: decreases pressure that results from other ocular diseases or trauma, aiding in disease control.

Latanoprost may cause ocular and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye itching: pruritus of the peri‑ocular area. - Increased eyelash growth: longer, darker lashes. - Darkening of iris: gradual brownish pigmentation. - Blurred vision: temporary visual disturbance after instillation. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Uveitis: inflammation of the uveal tract. - Corneal edema: swelling of the cornea affecting clarity. - Macular edema: fluid accumulation in the central retina. - Allergic reaction: severe hypersensitivity with swelling or rash. - Vision loss: sudden decrease in visual acuity. - Persistent ocular pain: ongoing discomfort beyond initial period.

Before using Lifog, consider the following precautions to ensure safe and effective therapy.

- Contraindication: do not use in patients with known hypersensitivity to latanoprost or any component of the eye drop. - Pregnancy: safety has not been established; avoid use unless benefits outweigh risks. - Breastfeeding: insufficient data; caution advised if the patient is nursing. - Ocular surgery: discontinue at least 2 weeks before any intra‑ocular procedure. - Contact lens wear: avoid using the drops while wearing soft contact lenses; remove lenses before instillation. - Storage: Store below 25°C: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may diminish prostaglandin effect, reducing pressure‑lowering action. - Prostaglandin analogs combination: concurrent use can increase risk of ocular inflammation.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive intra‑ocular pressure reduction may cause hypotony. - Carbonic anhydrase inhibitors: combined therapy may enhance pressure‑lowering effect, requiring monitoring. - Systemic prostaglandin analogs: may increase ocular side effects such as iris pigmentation.